These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 7570296)

  • 1. Therapeutic approaches to asthma based on VLA-4 integrin and its counter receptors.
    Metzger WJ
    Springer Semin Immunopathol; 1995; 16(4):467-78. PubMed ID: 7570296
    [No Abstract]   [Full Text] [Related]  

  • 2. Timing of administration of anti-VLA-4 differentiates airway hyperresponsiveness in the central and peripheral airways in mice.
    Kanehiro A; Takeda K; Joetham A; Tomkinson A; Ikemura T; Irvin CG; Gelfand EW
    Am J Respir Crit Care Med; 2000 Sep; 162(3 Pt 1):1132-9. PubMed ID: 10988142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of delayed-type hypersensitivity with inhibitors of the VLA-4 integrin.
    Tamraz S; Arrhenius T; Chiem A; Forrest MJ; Gaeta FC; He YB; Lei J; Maewal A; Phillips ML; Vollger LW
    Springer Semin Immunopathol; 1995; 16(4):437-41. PubMed ID: 7570294
    [No Abstract]   [Full Text] [Related]  

  • 4. Design and synthesis of potent and selective inhibitors of integrin VLA-4.
    Wattanasin S; Weidmann B; Roche D; Myers S; Xing A; Guo Q; Sabio M; von Matt P; Hugo R; Maida S; Lake P; Weetall M
    Bioorg Med Chem Lett; 2001 Nov; 11(22):2955-8. PubMed ID: 11677134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-aryl 2,6-dimethoxybiphenylalanine analogues as VLA-4 antagonists.
    Doherty GA; Kamenecka T; McCauley E; Van Riper G; Mumford RA; Tong S; Hagmann WK
    Bioorg Med Chem Lett; 2002 Mar; 12(5):729-31. PubMed ID: 11858990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase-type plasminogen activator inhibits alpha 4 beta 1 integrin-mediated T lymphocyte adhesion to fibronectin independently of its catalytic activity.
    Olivier P; Bieler G; Müller KM; Hauzenberger D; Rüegg C
    Eur J Immunol; 1999 Oct; 29(10):3196-209. PubMed ID: 10540331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Squaric acid derivatives as VLA-4 integrin antagonists.
    Porter JR; Archibald SC; Childs K; Critchley D; Head JC; Linsley JM; Parton TA; Robinson MK; Shock A; Taylor RJ; Warrellow GJ; Alexander RP; Langham B
    Bioorg Med Chem Lett; 2002 Apr; 12(7):1051-4. PubMed ID: 11909715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of E-selectin, P-selectin, and very late activation antigen-4 in T lymphocyte migration to dermal inflammation.
    Issekutz AC; Issekutz TB
    J Immunol; 2002 Feb; 168(4):1934-9. PubMed ID: 11823529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of a peptidomimetic tricyclic tetrahydrobenzo[ij]quinoline as a VLA-4 antagonist.
    Ho WB; Broka C
    J Org Chem; 2000 Oct; 65(20):6743-8. PubMed ID: 11052128
    [No Abstract]   [Full Text] [Related]  

  • 10. Pathophysiological aspects of VLA-4 interactions and possibilities for therapeutical interventions.
    Kuijpers TW
    Springer Semin Immunopathol; 1995; 16(4):379-89. PubMed ID: 7570289
    [No Abstract]   [Full Text] [Related]  

  • 11. N-acyl phenylalanine analogues as potent small molecule VLA-4 antagonists.
    Chen L; Tilley JW; Huang TN; Miklowski D; Trilles R; Guthrie RW; Luk K; Hanglow A; Rowan K; Schwinge V; Wolitzky B
    Bioorg Med Chem Lett; 2000 Apr; 10(8):725-7. PubMed ID: 10782673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The integrin alpha 4 beta 1 (VLA-4) as a therapeutic target.
    Elices MJ
    Ciba Found Symp; 1995; 189():79-85; discussion 85-90, 174-6. PubMed ID: 7587639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical role of VLA-4 in erythropoiesis in vivo.
    Hamamura K; Matsuda H; Takeuchi Y; Habu S; Yagita H; Okumura K
    Blood; 1996 Mar; 87(6):2513-7. PubMed ID: 8630418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbacyclic peptide mimetics as VCAM-VLA-4 antagonists.
    Tilley J; Kaplan G; Fotouhi N; Wolitzky B; Rowan K
    Bioorg Med Chem Lett; 2000 Jun; 10(11):1163-5. PubMed ID: 10866372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diamine containing VLA-4 antagonists.
    Astles PC; Harris NV; Morley AD
    Bioorg Med Chem; 2001 Aug; 9(8):2195-202. PubMed ID: 11504657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the VLA-4 integrin in leucocyte recruitment and bronchial hyperresponsiveness in the guinea-pig.
    Milne AA; Piper PJ
    Eur J Pharmacol; 1995 Aug; 282(1-3):243-9. PubMed ID: 7498283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclic thioether peptide mimetics as VCAM-VLA-4 antagonists.
    Fotouhi N; Joshi P; Tilley JW; Rowan K; Schwinge V; Wolitzky B
    Bioorg Med Chem Lett; 2000 Jun; 10(11):1167-9. PubMed ID: 10866373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-inflammatory activity of c(ILDV-NH(CH2)5CO), a novel, selective, cyclic peptide inhibitor of VLA-4-mediated cell adhesion.
    Haworth D; Rees A; Alcock PJ; Wood LJ; Dutta AS; Gormley JJ; Jones HB; Jamieson A; Reilly CF
    Br J Pharmacol; 1999 Apr; 126(8):1751-60. PubMed ID: 10372817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct fibronectin splicing variants: potential targets for therapeutic immunomodulation in organ allograft recipients.
    Coito AJ; Korom S; Van de Water L; Kupiec-Weglinski JW
    Transplant Proc; 1997; 29(1-2):1060-1. PubMed ID: 9123198
    [No Abstract]   [Full Text] [Related]  

  • 20. N-benzylpyroglutamyl-L-phenylalanine derivatives as VCAM/VLA-4 antagonists.
    Chen L; Tilley JW; Guthrie RW; Mennona F; Huang TN; Kaplan G; Trilles R; Miklowski D; Huby N; Schwinge V; Wolitzky B; Rowan K
    Bioorg Med Chem Lett; 2000 Apr; 10(8):729-33. PubMed ID: 10782674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.